Abstract：
Gastroesophageal (GE) and pancreatobiliary (PB) cancers represent a significant clinical challenge. In this context, it is critical to understand the key molecular targets within these malignancies including how they are assayed for as well as the clinical actionability of these targets. Integrating biomarkers into the standard of care presents a critical avenue for refining treatment paradigms. This review aims to explore these complexities, offering insights into the optimal sequencing of chemotherapy and targeted therapies and their utility in the management of GE and PB cancers. The timely integration of promising investigational therapies into clinical practice has broader implications around strategies for future clinical trial designs, which would pave the way for advancements in the management of GE and PB cancers. This review provides guidance in navigating the evolving landscape of GE and PB cancer care, which ultimately will drive forward progress in the field and lead to improved patient outcomes.
摘要：
胃食管（GE）和胰胆管（PB）癌症代表了重大的临床挑战。在这种情况下，了解这些恶性肿瘤中的关键分子靶标,包括如何对其进行检测以及这些靶标的临床可操作性至关重要.将生物标志物整合到护理标准中提出了改进治疗范例的关键途径。这篇综述旨在探讨这些复杂性，提供有关化疗和靶向治疗的最佳测序及其在GE和PB癌症管理中的实用性的见解。将有希望的研究疗法及时整合到临床实践中，对未来临床试验设计的策略具有更广泛的意义。这将为GE和PB癌症管理的进步铺平道路。这篇综述为指导GE和PB癌症护理的发展提供了指导，这最终将推动该领域的进展，并改善患者的预后。
